Status:

RECRUITING

Melodi Matrix™ in Breast Reconstruction

Lead Sponsor:

Melodi Health, Inc.

Conditions:

Breast Reconstruction

Eligibility:

FEMALE

22+ years

Phase:

NA

Brief Summary

Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.

Eligibility Criteria

Inclusion

  • Female.
  • Age 22 or older at the time of enrollment.
  • Is scheduled to undergo unilateral or bilateral mastectomy (including prophylactic) with immediate two-stage post-mastectomy alloplastic prepectoral breast reconstruction.
  • Is able to and willing to comply with the study requirements and providing informed consent.

Exclusion

  • Has prior history of neoadjuvant radiotherapy.
  • Has had prior history of failed tissue expansion or breast implantation at the intended reconstruction site.
  • Has an active abscess or infection requiring antibiotics anywhere in their body within 30 days.
  • Has a Body Mass Index (BMI) \< 14 or \> 40.
  • Is pregnant or is nursing; or plans to become pregnant during the course of the study.
  • Has any connective tissue/autoimmune disorder or rheumatoid disease.
  • Has known allergies to study device materials.
  • Is participating in another interventional research study that may interfere with study endpoints.
  • Has limited life expectancy or co-morbid conditions, social/psychological problems, or cognitive impairments that precludes participation.
  • Has a medical condition or is taking medications that would result in elevated risk and/or affect the validity of the study.
  • Intraoperative assessment demonstrates unfavorable conditions (i.e., poor mastectomy skin flap thickness or viability) for immediate, two-stage post-mastectomy alloplastic prepectoral reconstruction in any breast.

Key Trial Info

Start Date :

August 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2028

Estimated Enrollment :

702 Patients enrolled

Trial Details

Trial ID

NCT06027996

Start Date

August 9 2024

End Date

June 1 2028

Last Update

December 8 2025

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Stanford University

Palo Alto, California, United States, 94304

2

University of Michigan Health

Ann Arbor, Michigan, United States, 48109

3

Mayo Clinic

Rochester, Minnesota, United States, 55905

4

Northwell Health

Staten Island, New York, United States, 10305

Melodi Matrix™ in Breast Reconstruction | DecenTrialz